Bendazac Inhibitor

Bendazac is an anticataract drug. It may act by preventing protein denaturation.

Marques C, Ramalho J S, Pereira P, et al. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac[J]. Documenta Ophthalmologica, 1995, 90(4):395-404.
Marques C, Ramalho J S, Pereira P, et al. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac[J]. Documenta Ophthalmologica, 1995, 90(4):395-404.
Lewis B S, Rixon K C, Harding J J. Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract[J]. Experimental Eye Research, 1986, 43(6):0-979.
Lewis B S, Rixon K C, Harding J J. Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract[J]. Experimental Eye Research, 1986, 43(6):0-979.

Small volumes of Bendazac, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5758673 is an inhibitor targeting Bendazac.